Market Closed -
Hong Kong S.E.
09:09:00 03/05/2024 BST
|
5-day change
|
1st Jan Change
|
0.435
HKD
|
+17.57%
|
|
+20.83%
|
-29.84%
|
Fiscal Period: December |
2021
|
2022
|
---|
Capitalization
1 |
12,815
|
2,957
|
Enterprise Value (EV)
1 |
10,023
|
1,687
|
P/E ratio
|
-2.13
x
|
-1.03
x
|
Yield
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
EV / Revenue
|
-
|
-
|
EV / EBITDA
|
-4.5
x
|
-0.72
x
|
EV / FCF
|
-8,219,769
x
|
-1,079,723
x
|
FCF Yield
|
-0%
|
-0%
|
Price to Book
|
10.5
x
|
-4.43
x
|
Nbr of stocks (in thousands)
|
1,158,115
|
1,292,635
|
Reference price
2 |
11.07
|
2.287
|
Announcement Date
|
19/04/22
|
20/04/23
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
---|
Net sales
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-61.76
|
-303.1
|
-2,226
|
-2,337
|
EBIT
1 |
-62.83
|
-304.6
|
-2,239
|
-2,366
|
Operating Margin
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-48.58
|
-912.9
|
-6,016
|
-2,452
|
Net income
1 |
-48.58
|
-912.9
|
-6,016
|
-2,452
|
Net margin
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.0641
|
-1.205
|
-5.195
|
-2.225
|
Free Cash Flow
|
-
|
-518.4
|
-1,219
|
-1,562
|
FCF margin
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
Announcement Date
|
25/10/21
|
25/10/21
|
19/04/22
|
20/04/23
|
Fiscal Period: December |
2021 S1
|
2021 S2
|
2022 S1
|
2022 S2
|
2023 S1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
0.257
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-758.7
|
-1,065
|
-1,081
|
-795
|
-517.5
|
Operating Margin
|
-
|
-
|
-
|
-
|
-201,372.37%
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
Net income
|
-
|
-
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
EPS
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
-
|
29/03/22
|
23/08/22
|
28/03/23
|
22/08/23
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
1 |
52.5
|
363
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
2,791
|
1,270
|
Leverage (Debt/EBITDA)
|
-0.85
x
|
-1.198
x
|
-
|
-
|
Free Cash Flow
|
-
|
-518
|
-1,219
|
-1,562
|
ROE (net income / shareholders' equity)
|
-
|
174%
|
-5,090%
|
-890%
|
ROA (Net income/ Total Assets)
|
-
|
-27.7%
|
-42.8%
|
-29.5%
|
Assets
1 |
-
|
3,293
|
14,046
|
8,324
|
Book Value Per Share
2 |
-0.0900
|
-
|
1.050
|
-0.5200
|
Cash Flow per Share
2 |
0.2000
|
-
|
2.390
|
1.240
|
Capex
1 |
6.82
|
114
|
59.3
|
77
|
Capex / Sales
|
-
|
-
|
-
|
-
|
Announcement Date
|
25/10/21
|
25/10/21
|
19/04/22
|
20/04/23
|
|
1st Jan change
|
Capi.
|
---|
| -29.84% | 72.22M | | +8.96% | 105B | | -1.43% | 104B | | +4.40% | 22.94B | | -12.15% | 22.34B | | -4.36% | 19.25B | | -39.98% | 17.08B | | -10.04% | 16.96B | | +6.79% | 14.16B | | +38.61% | 12.63B |
Bio Therapeutic Drugs
|